Best Practice & Research Clinical Gastroenterology
Volume 25, Supplement 1 , Pages S15-S18, April 2011

Novel developments in IBD-related sclerosing cholangitis

Dept. of Gastroenterology & Hepatology, Academic Medical Center, P.O. Box 22700, Amsterdam, The Netherlands

Primary sclerosing cholangitis is often regarded as an autoimmune disorder and occurs frequently in relation to inflammatory bowel disease. The ongoing fibro-obliterative process of the biliary tree ensues in liver failure or cholangiocarcinoma in 12-18 years. PSC patients with concurrent IBD are at increased risk of developing colorectal carcinoma. Ursodeoxycholic acid, which is widely prescribed in PSC, is despite intensive clinical research still not proven to halt disease progression. Nor-ursodeoxycholic acid seems promising in animal models of cholestasis. Novel compounds that are involved in the immunological axis between the gut and the liver await clinical testing in PSC.

Keywords:  Primary sclerosing cholangitis , Novel therapy , IBD

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6918(11)70005-1

doi:10.1016/S1521-6918(11)70005-1

Best Practice & Research Clinical Gastroenterology
Volume 25, Supplement 1 , Pages S15-S18, April 2011

Article Tools